Podcasts about BCG

In this episode of Better Edge, Joshua Meeks, MD, PhD, discusses the implications of the FDA's recent approval of TAR-200, a novel therapy for bladder cancer. Having played a key role in the clinical trials and development of this treatment, Dr. Meeks provides an in-depth look at this breakthrough's potential to transform patient care, especially for those with BCG-unresponsive bladder cancer.

In this eye-opening episode, Benjamin sits down with Stan to explore the ever-evolving world of HR, AI, and self-development. From a failed startup in personal training to building an HR tech platform that's redefining how we quantify learning impact, Stan shares how data, personalisation, and AI can turn HR into a measurable business driver. Together, they unpack why soft skills—not certificates—are the currency of tomorrow, and why HR must learn to speak the language of CEOs.Expect candid insights on vanity learning, digital performance metrics, and why many confuse self-improvement with status signalling. This conversation is for anyone curious about the real ROI of learning, the future of work, and how to stay relevant in an age where even BCG analysts are being outpaced by AI. Tune in now!More about Stan and Evolve:https://www.linkedin.com/in/stan-suchkov/https://www.linkedin.com/company/evolveplatform/https://evolveplatform.ai/Paul's Job:⁠https://paulsjob.ai/⁠⁠https://www.instagram.com/paulsjob/⁠⁠https://www.linkedin.com/company/paulsjob/⁠https://www.youtube.com/@paulsjob/featuredHR Visionaries Deutschland:https://open.spotify.com/show/2OHMNxXljWpKs1hU5eDqm2?si=8f11934c029d4729https://podcasts.apple.com/de/podcast/hr-visionaries-deutschland/id1621089768https://www.youtube.com/@paulsjob/featured

M&A activity is waking up, but many companies are reluctant to leap into the fray. Daniel Friedman, BCG's global leader of transactions and integrations, explains why bold moves now could pay off. Waiting may feel safe, but the cost could be forfeiting once-in-a-decade opportunities. Learn More: Daniel Friedman: https://on.bcg.com/4mWHyGW Mid-2025 M&A Insights: https://on.bcg.com/3V6ENGF BCG's Latest Thinking on M&A: https://on.bcg.com/4ndP9QU BCG's M&A Sentiment Index: https://on.bcg.com/3VEdBzb 00:00-02:56 Intro/Daniel's ‘So What' 02:57-04:34 What is different now vs. the beginning of the year? 04:35-06:13 How quickly will the market recover? 06:14-08:20 What regions and sectors are particularly active? 08:21-09:01What are risks that could impede recovery? 09:02-10:26 What is wrong with waiting on the sidelines? 10:27-12:00 Do downturn deals tend to deliver more value than boom time deals? 12:01-13:25 What can a company to do ensure that it finds the right deal? 13:26-17:02 How has M&A changed in a more uncertain world? 17:03-18:03 How will AI evolve? 18:04-19:45 What are the winners doing right in this new environment? 19:46-21:16 The ‘Now What' 21:17-21:33 OutroThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us a textWant to land a consulting role in Canada? This episode walks you through everything you need to know about breaking into consulting in 2025.We cover:The current Canadian consulting market and how it differs from the U.S. and U.K.3 recruiting power moves you can apply immediatelyKey target schools, top firms, and the hiring timeline2025 salary preview across McKinsey, Bain, BCG, and moreFor the complete playbook, download Management Consulted's 2025 Canada Recruitment Roadmap – free. It's packed with firm-by-firm insights, deadlines, and strategies to help you land an offer in Toronto, Montreal, Vancouver, or Calgary.Additional Resources:Review 2025 Canada consulting application deadlinesJoin Black Belt, an expert prep program that's helped hundreds land offers in CanadaPartner Links:Stax is hiring! See open roles and requirementsListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

As one of the world's great technology companies, Siemens needs no introduction, but is notable for not only a holistic approach to sustainability but, in particular, for the way sustainability has been integrated into the heart of the business model. But how do they drive the sustainability agenda with more than 300,000 people? How do they innovate at such a scale? How do they bring technology and sustainability together in practice? And how are their efforts received by their customers, employees, and investors?We are delighted to be joined by Dr. Eva Riesenhuber, the Global Head of Sustainability at Siemens, to help share insights into these questions and more. Eva started her career as a lawyer, with a doctorate in international public law and more than a decade of experience as a finance lawyer in New York. From there, Eva has worked as an SVP in the Siemens M&A department, as CFO of Next47, the Siemens-owned venture capital firm, and as the Head of Investor Relations at Siemens. She became Global Head of Sustainability in October 2022 and is a member of the supervisory board of Siemens Mobility GmbH.Building on her strong foundations in law and value creation, Eva speaks with Vincent Chin, Managing Director & Senior Partner at BCG and Asia Pacific Regional Leader of the BCG Henderson Institute, about the role of innovation, the people agenda, and the shareholder perspective in Siemens' sustainability efforts. They cover decarbonizing in conjunction with customers, building new approaches to product design, ensuring that efforts are globally inclusive, and the role of AI. Eva's unique viewpoints make this essential listening for those looking to activate large organizations to deliver a competitive advantage through sustainability.

For Chief Operating Officers, CFOs, and heads of warehousing, logistics, and retail across Asia, 2026 will be defined by one overarching theme: strategic resilience through intelligent automation. The region's blistering e-commerce growth, coupled with persistent geopolitical and supply chain volatilities (as highlighted by analysts like BCG regarding the fragmentation of global trade), is forcing a fundamental rethink of operational models.By 2026, we will see the full maturation of trends nascent in 2024. AI and machine learning will transition from pilot projects to the core operational nervous system of high-performance warehouses. Their primary role will be predictive: forecasting demand spikes with greater accuracy, pre-empting maintenance on automated guided vehicles (AGVs) and robotics to prevent downtime, and dynamically optimising inventory placement to slash picking times and maximise cube utilisation.In this PodChats for FutureIoT, we are joined by Ms Vivien Tay, APAC Vertical Lead for Warehousing, Transport & Logistics, Zebra Technologies.1.       At the operational level, briefly describe the business environment today from the perspective of the supply chain. 2.       Given the fragmentation of global trade routes, how are organisations in Asia leveraging AI and data analytics to build more regionalised and resilient supply chains to mitigate geopolitical risks?3.       How are enterprises integrating predictive analytics into daily operations to move from reactive problem-solving to pre-empting issues in inventory management, maintenance, and order fulfilment?4.       Given that most organisations have existing warehouse management systems (WMS), name one proven approach for integrating new AI-powered software with existing legacy systems without causing disruptive downtime.5.       Beyond labour displacement, can you share a proven approaches/framework for measuring the full ROI of automation investments, including improved accuracy, enhanced safety, reduced shrinkage, and increased employee retention?6.       Many technologies fail as they move from pilot to scale, how can organisations ensure that the automation technologies they implement today are scalable and flexible enough to adapt to unpredictable demand cycles and future business growth?7.       With increasing focus on ESG, how are organisations using automation to measure and reduce their carbon footprint through optimised energy use, waste reduction, and smarter inventory planning?8.       As operations become more reliant on connected IoT devices and AI, what enhanced cybersecurity measures can be implemented to protect against operational shutdowns and data breaches?9.       How is investment in real-time visibility technology directly translating into a superior and more transparent customer experience for e-commerce and retail partners?10.   Our topic is strategic resilience through intelligent automation what is your advise for warehousing and supply chain leaders in 2026?

LinkedIn Dennis Hillemann: (1) Dennis Hillemann | LinkedInKontaktdaten Dennls Hillemann:Rechtsanwalt Dennis Hillemann c/o Rechtsanwälte Advant BeitenNeuer Wall 7220354 Hamburg E-Mail: dennis.hillemann@advant-beiten.com www.advant-beiten.com;Telefon +49.(0)40.68 87 45 - 132KI im öffentlichen Dienst: Warum Deutschland jetzt handeln mussDeutschland steht vor einer gewaltigen Herausforderung: 700.000 fehlende Fachkräfte im öffentlichen Dienst, stagnierende Produktivität und eine Verwaltung, die im internationalen Vergleich als besonders veränderungsresistent gilt. In dieser Episode analysiere ich, warum Künstliche Intelligenz nicht länger eine Option, sondern eine zwingende Notwendigkeit für die Zukunftsfähigkeit unseres Staates ist.Basierend auf aktuellen Studien von KPMG, BCG und SAS zeige ich auf, dass die größten Hürden bei der KI-Implementierung nicht technischer, sondern menschlicher Natur sind. Während 37% der deutschen Unternehmen bereits KI nutzen, hinkt der öffentliche Dienst deutlich hinterher. Die Gründe: Verlustängste, rechtliche Bedenken und eine tief verwurzelte Kultur der Risikovermeidung.Ich erkläre, warum gerade Beamte besondere Vorbehalte haben – von der Sorge um 165.000 potenziell gefährdete Stellen bis zu berechtigten Fragen zur Transparenz algorithmischer Entscheidungen. Gleichzeitig zeige ich konkrete Wege auf, wie wir diese Transformation erfolgreich gestalten können: durch transparente Kommunikation, massive Investitionen in Qualifizierung, partizipative Einbindung der Mitarbeitenden und rechtssichere Rahmenbedingungen.Die zentrale Botschaft: Deutschland hat keine Wahl. Die Alternative zu einer KI-gestützten Modernisierung ist ein handlungsunfähiger Staat. Es ist Zeit, die "German Angst" zu überwinden und die Chancen der Digitalisierung endlich zu nutzen.

Willkommen zur neuen Folge von Choose Germany – dem Business-Punk-Podcast für alle, die dieses Land nicht schlechtreden, sondern neu gestalten wollen. In Partnerschaft mit dem Startup-Verband und powered by BCG holen wir Deutschlands mutigste Macher:innen ans Mikro.Zu Gast: Fabian Kienbaum – Unternehmer und People-Leadership-Experte. Mit Carsten spricht er darüber, warum Deutschland sofort Tempo aufnehmen muss: weniger Bürokratie, wettbewerbsfähige Energie- und Steuerrahmen, schnellere Visa – und vor allem ein klares Zielbild: Lust auf Zukunft.Fabian ordnet ein, warum wir „mit dem Rücken zur Wand“ stehen, was ein Regulierungs-Moratorium bringen könnte und wieso Wettbewerbsfähigkeit zur Top-Priorität der Politik werden muss. Er erklärt, wie qualifizierte Zuwanderung praktisch scheitert – von IHK-Schleifen bis zähen Visa – und was es braucht, um Talente wirklich willkommen zu heißen.Beim Thema Kapital plädiert er für europäisches Denken: Kapitalströme harmonisieren, institutionelles Geld in Innovation bringen – und positive Signale (z. B. Stiftungsvermögen in VC) skalieren. Planungssicherheit statt Fragmentierung.Sein Appell an Unternehmen: HR als Business-Accelerator denken. Sichtbarkeit schaffen, Dialogfähigkeit aufbauen, Personal- und Employer-Branding verzahnen – denn Menschen folgen Menschen, und Selbstwirksamkeit stiftet Motivation.Und: KI & Bildung. Deutschland muss leapfroggen – Technologie in Verwaltung und Mittelstand radikal anwenden und das Bildungssystem auf Anwendungskompetenz ausrichten. Nur so bleibt „Made in Germany“ mehr als ein Etikett – eine Story, die wieder Talente und Investitionen anzieht.Es geht um:

Do you avoid conflict—or use it to grow your influence? In this episode, AJ and Johnny share a science-backed framework for conflict resolution that transforms tense moments into opportunities for trust and leadership. Drawing on John Gottman's research on relationships and Google's Project Aristotle findings on high-performing teams, they reveal why conflict isn't a problem to eliminate—it's a chance to deepen respect and build long-term influence. You'll learn a step-by-step system to handle everyday workplace and relationship conflicts without burning bridges: lead with value, accept responsibility, show empathy, and present solutions that create buy-in. With stories from clients like Marcus, a consultant at BCG, AJ and Johnny show how mastering conflict resolution can make you the person others turn to when stakes are high. If you've ever felt conflict-averse, this episode gives you practical tools to stay calm, confident, and in control. What to Listen For [00:00:00] Why avoiding conflict costs you influence [00:00:56] How conflict avoidance limits your “career chessboard” moves [00:01:27] The science of conflict: shifting from “me vs. you” to “us vs. the problem” [00:02:43] The High-Value Conflict Framework explained [00:03:28] Step 1: Lead with value to disarm defensiveness [00:03:54] Step 2: Accept responsibility without weakness [00:06:23] Step 3: Use empathy and “we” language to build trust [00:07:26] Step 4: Present options, not ultimatums [00:09:18] Why well-resolved conflicts create stronger bonds [00:11:03] Client story: how Marcus became the go-to conflict solver [00:11:29] Why mastering conflict is the ticket to influence A Word From Our Sponsors Stop being over looked and unlock your X-Factor today at ⁠unlockyourxfactor.com⁠  The very qualities that make you exceptional in your field are working against you socially.  Visit the ⁠artofcharm.com/intel ⁠for a social intelligence assessment and discover exactly what's holding you back. Indulge in affordable luxury with Quince. Upgrade your wardrobe today at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠quince.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for free shipping and hassle-free returns. Grow your way - with Headway! Get started at ⁠makeheadway.com/CHARM ⁠and use my code CHARM for 25% off. Ready to turn your business idea into reality? Sign up for your $1/month trial at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Need to hire top talent—fast? Claim your $75 Sponsored Job Credit now at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indeed.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. This year, skip breaking a sweat AND breaking the bank. Get your summer savings and shop premium wireless plans at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mintmobile.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Save more than fifty percent on term life insurance at ⁠SELECTQUOTE.COM/CHARM⁠ TODAY to get started  Curious about your influence level?  Get your Influence Index Score today! Take this 60-second quiz to find out how your influence stacks up against top performers at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠theartofcharm.com/influence⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check in with AJ and Johnny! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on TikTok⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

What if the real secret to exceptional leadership isn't control, charisma, or even performance—but generosity? Could the “soft stuff” like listening, empathy, and vulnerability truly drive the hardest results in business? In this episode of the Delighted Customers podcast, I dig into that very question with Joe Davis, legendary former Senior Partner at Boston Consulting Group, co-founder of BCG's Washington D.C. office, and author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain”. Joe shares his own journey from traditional, results-driven leadership to a generous, people-centered model—and why unlocking your team's full human potential just might be the most powerful business move you can make. We explore how the traits of generosity drive not only team happiness and loyalty, but also real bottom-line outcomes, making this conversation essential listening for leaders and aspiring leaders at every level. Why should you tune in to this episode? Joe has four decades of hands-on experience innovating in both the private and public sectors, founding major business initiatives within BCG, and working closely with Fortune 500 C-suite leaders. He distills this wisdom into practical strategies—whether you're leading a team of three or a global enterprise of 100,000. His stories from the front lines of consulting, combined with actionable steps for building trust and humanity in the workplace, will change the way you think about leadership forever. Here are three compelling questions Joe answers on the show: Why should organizations and their C-suite invest in “generous leadership” when they're held accountable for hard business outcomes, not just a healthy culture? What are the seven key traits that separate good leaders from exceptional, generous leaders—and how do they play out in real-world scenarios? How can listening, vulnerability, and small acts of recognition dramatically improve your team's performance and engagement? Listen now and subscribe to the Delighted Customers podcast on Apple Podcasts and Spotify! You'll find this episode—and every episode—on all your favorite podcast platforms. If you find value in these conversations, please leave a review and share with a friend or colleague who wants to rethink what great leadership really looks like. Meet Joe Davis Joe Davis is a veteran senior partner at Boston Consulting Group (BCG), where he spent 37 years shaping strategy, developing talent, and transforming organizations at the highest level. Joe co-founded BCG's Washington D.C. office and launched the firm's North American Public Sector business, as well as leading BCG North America. Passionate about advancing equity and inclusion, he also founded and chaired BCG's Center for Inclusion and Equity. Joe is a Harvard Business School graduate and has been at the forefront of helping organizations evolve from top-down, authoritarian structures to cultures of trust, inclusion, and generosity. His experience spans advising CEOs of major corporations to hands-on coaching with emerging leaders. He is the author of “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain,” a groundbreaking book that reimagines the connection between caring leadership and delivering results. Joe is currently an advisor and coach to BCG's rising partners, teaching them how to inspire, motivate, and build lasting client relationships. You can reach Joe and learn more about his work via his LinkedIn profile or his website at joedavis.com. Show References and Resources “The Generous Leader: Seven Ways to Give of Yourself for Everyone's Gain” by Joe Davis Amazon Link Joe Davis on LinkedIn: https://www.linkedin.com/in/joe-davis-bcg/ Joe's personal website: https://joedavis.com Harvard Business School: https://www.hbs.edu Boston Consulting Group (BCG): https://www.bcg.com Michigan State University's Trust and Leadership Education: https://broad.msu.edu CEO Joaquin Duato, Johnson & Johnson: https://www.jnj.com/leadership/joaquin-duato Scott Kirby, CEO of United Airlines: https://www.united.com/ual/en/us/fly/company/about/leadership.html Sheila Bair, former FDIC chair: https://www.fdic.gov/about/leadership/sheila-bair/ Thank you for listening to the Delighted Customers podcast!

Becirovic, CIO at Boston Consulting Group, sat down with senior editor Lucas Mearian at Foundry's CIO 100 event to discuss BCG's AI strategy, which emphasizes internal proof-of-concept before external application and focuses on journey-led and experience-led platforms. Becirovic also highlighted the importance of data strategy, upskilling, and managing AI costs effectively. Featuring Merim Becirovic: https://www.linkedin.com/in/merimb/ Lucas Mearian: https://www.linkedin.com/in/lucasmearian/

Warren Zenna sits down with Amy Hsuan, Chief Customer & Revenue Officer at Mixpanel, to unpack what a truly unified revenue engine looks like. Amy shares how org design must follow strategy, why GTM is a core differentiator, and how aligning marketing, sales, success, and services creates consistent end‑to‑end customer experiences that actually win.Amy traces her path from journalism to BCG to Mixpanel, revealing how curiosity, cross‑functional leadership, and a customer‑first mindset shaped her Chief Customer & Revenue Officer role. She explains the shift from “hard” product differentiation to human‑driven trust, and how relationships, not features, become defensible moats in crowded markets.They dig into practical playbooks: orchestrating handoffs, clarifying tone across touchpoints, and reducing executive silos to move faster. Amy outlines a strategy‑to‑execution flywheel, her 80/20 time model for long‑ vs short‑term, and how consistent advisory through complex, multi‑stakeholder cycles sustains momentum and predictability.Amy also shares a grounded view on AI: use it to accelerate research, analysis, and context so leaders increase decision velocity—while humans own listening, rapport, creative adaptation, and navigating org dynamics. If you're a CRO, aspiring CRO, or CEO aiming to modernize revenue leadership, this conversation is a blueprint.

Neste episódio 307 falamos do vídeo dos fãs do Will Smith com IA e os novos S's segundo a BCG e a Google.

Una niña regia con veintitantos primos y domingos en casa de la abuela. Una joven que zigzagueó entre diplomacia, banca, consultoría y startups, hasta que el cierre inesperado de la empresa en la que trabajaba le mostró una puerta que no pensaba abrir: la de fundar. ¡Y en Silicon Valley!Su empresa de biotecnología nació con una presentación de 12 filminas, tres socios improbables y un cheque inicial. Hoy los millones de dólares de inversión se han multiplicado, y también el número de patentes y las alianzas globales.Vive con su marido y tres hijos lejos de México, pero no del idioma español; ni de las arepas venezolanas aportadas por el papá o el altar de Muertos promovido por la mamá. De su abuelo aprendió que la iniciativa es importante, pero es más importante la terminativa. Y eso, en su historia, no es una sola frase: ha sido la diferencia entre imaginar y lograr.Acerca de Sofía: Es cofundadora y presidenta de Brightseed, donde lidera el desarrollo de soluciones con inteligencia artificial para descubrir moléculas bioactivas con aplicaciones nutricionales y terapéuticas.Antes impulsó la comercialización de proteínas vegetales innovadoras y trabajó en BCG, donde fue miembro fundadora del BCG Henderson Institute. También ha sido asesora especial de la ONU en colaboración con el sector privado.Es licenciada en Filosofía, Política y Economía por la Universidad de Pensilvania y tiene un MBA por Stanford. Ha sido reconocida como Young Global Leader por el Foro Económico Mundial y ha participado como ponente en foros internacionales de nutrición, IA y asuntos globales.

Nos vemos en Summit Regias el 5 de septiembre en el nuevo Hotel Intercontinental. Asegura tu entrada aquí: ⁠⁠https://www.summitregias.comUna niña regia con veintitantos primos y domingos en casa de la abuela. Una joven que zigzagueó entre diplomacia, banca, consultoría y startups, hasta que el cierre inesperado de la empresa en la que trabajaba le mostró una puerta que no pensaba abrir: la de fundar. ¡Y en Silicon Valley!Su empresa de biotecnología nació con una presentación de 12 filminas, tres socios improbables y un cheque inicial. Hoy los millones de dólares de inversión se han multiplicado, y también el número de patentes y las alianzas globales.Vive con su marido y tres hijos lejos de México, pero no del idioma español; ni de las arepas venezolanas aportadas por el papá o el altar de Muertos promovido por la mamá. De su abuelo aprendió que la iniciativa es importante, pero es más importante la terminativa. Y eso, en su historia, no es una sola frase: ha sido la diferencia entre imaginar y lograr.Acerca de Sofía: Es cofundadora y presidenta de Brightseed, donde lidera el desarrollo de soluciones con inteligencia artificial para descubrir moléculas bioactivas con aplicaciones nutricionales y terapéuticas.Antes impulsó la comercialización de proteínas vegetales innovadoras y trabajó en BCG, donde fue miembro fundadora del BCG Henderson Institute. También ha sido asesora especial de la ONU en colaboración con el sector privado.Es licenciada en Filosofía, Política y Economía por la Universidad de Pensilvania y tiene un MBA por Stanford. Ha sido reconocida como Young Global Leader por el Foro Económico Mundial y ha participado como ponente en foros internacionales de nutrición, IA y asuntos globales.

Joining Simon around the After Dinner Leadership table is Joe Davis, a former Boston Consulting Group Managing Director & Senior Partner who once led BCG's operations across the U.S., Canada, and Mexico and served on the firm's Executive Committee. Together, they explore the generous leader, offering direct feedback as a gift, discerning the right moment to give it, and embracing deep, patient listening as the quiet acts that create space for others to truly flourish.Joe Davis - Linkedinjoedavis.comThe Generous LeaderSend us a textConnect with us on LinkedIn Follow us on Instagram Subscribe on YouTube If you would like to feature on the Podcast, please get in touch! mailto: info@withleadership.co.uk Thank you for listening!

Starboard is building AI-first infrastructure to transform global trade by improving the productivity of freight forwarders—the central coordinators who connect 15-20 different parties in every international trade transaction. With 15 years of experience in the industry, including roles at Maersk, BCG, and Flexport, Sumeet Trehan saw an opportunity to modernize an industry that has invested heavily in physical infrastructure but neglected technological innovation. The company has raised $5.5 million and is approaching $1 million ARR while creating an entirely new category they call "AI-first forwarders." Topics Discussed: Building AI infrastructure to automate freight forwarding coordination and quoting processes Creating a new category in the traditional, relationship-driven logistics industry Go-to-market strategies for selling to an "old boys club" industry that operates differently from typical SaaS markets The founder's decision to personally handle the first 20-30 sales before hiring any sales staff Vision for transforming global trade by creating a comprehensive platform for small-to-mid-sized importers   GTM Lessons For B2B Founders: Cold calling still works in traditional industries: Starboard generates significant top-of-funnel activity through direct cold calling, with freight forwarders actually appreciating the personal touch. Sumeet's team achieves a 10% pickup rate and converts 15-20% of answered calls to discovery meetings by being upfront about the cold call nature and immediately focusing on business outcomes. The approach works because their target market—freight forwarders—are accustomed to making and receiving cold calls as part of their daily business operations. Door-to-door prospecting remains viable for relationship-driven markets: In industries where personal relationships dominate, physical presence can be a differentiator. Starboard literally brings donuts to prospects' offices, which works because their target market values face-to-face interactions. This approach only makes sense when your industry culture supports it and when the lifetime value of customers justifies the time investment. Founders should personally execute early sales to understand the playbook: Rather than immediately hiring sales staff after raising funding, Sumeet chose to personally close the first 20-30 deals. This allowed him to deeply understand customer pain points, refine the sales process, and develop a replicable methodology before bringing on sales team members. Only after proving out the top-of-funnel motion did he hire his first SDR, and only after closing 15-20 deals did he hire a sales leader. Physical implementation presence drives early-stage product adoption: For complex B2B products still achieving product-market fit, being physically present during implementation creates stronger relationships and better feedback loops. Starboard's team travels to be on-site when clients first use the product, which helps with both adoption rates and product development insights. They maintain ongoing communication through WhatsApp and Teams channels rather than Slack, adapting to their customers' preferred communication methods. Category creation requires education over product promotion: Starboard's marketing strategy focuses entirely on educating the market about AI's potential impact on logistics rather than promoting their specific product. By speaking at events, writing blogs, and participating in podcasts about industry transformation rather than Starboard features, they position themselves as thought leaders. This approach builds trust and creates demand for the category before potential customers are ready to evaluate specific solutions. Sequencing product development based on customer feedback: The company's current quoting product serves as a wedge, with plans to expand into marketplace functionality and then full operations automation. Each expansion builds on customer relationships and data from the previous phase. This measured approach to product development ensures each step creates value while building toward the larger vision of comprehensive trade infrastructure.   //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co   //   Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM 

How do law firms really decide what partners get paid?Partner compensation is one of the most important and controversial topics in the legal industry. The way firms structure pay doesn't just impact income; it shapes firm culture, collaboration, and long-term profitability.In this episode of Financially Legal, Emery Wager sits down with Hugh Simons (former BCG consultant, law firm CEO, and prolific writer on law firm economics) to unpack:The major compensation models (lockstep, points-based, and eat-what-you-kill)Why open vs. closed pay systems matter more than you thinkHow incentives drive collaboration, culture, and firm growthWhere partner compensation is headed in the next decadeWhether you're a managing partner, CFO, or simply curious how partner pay really works, this episode pulls back the curtain on a system that defines the legal industry.

Transformation isn't a gamble—it's science. Kristy Ellmer, a leader with BCG Transform, unpacks the research behind what really makes change work: involving employees in the journey, preparing for the “messy middle,” and building emotional and practical support into the process. Successful efforts focus equally on shifting behaviors and mindsets, not just strategy and structure. Learn More: Kristy Ellmer: https://www.bcg.com/about/people/experts/kristy-ellmer BCG's Latest Thinking on Business Transformation: https://www.bcg.com/capabilities/business-transformation/insights To Keep Transformations on Track, Incentives Are Crucial: https://www.bcg.com/publications/2025/incentives-are-crucial-for-transformation-success The Transformation Paradox: How to Grow When the Growing Gets Tough: https://www.bcg.com/publications/2025/transformation-paradox-how-grow-when-growing-gets-tough This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us a textGetting invited to a second round consulting interview is a huge achievement, but it's not the finish line. The final round is where the offer is won or lost. In this episode, Jenny Rae shares exactly how to prepare for 2nd-round consulting interviews, including advanced case interview strategies and fit interview best practices. Whether you're interviewing with McKinsey, Bain, BCG, or another top consulting firm, this guide will help you turn your second-round invite into a full-time offer.Additional Resources:Start your Case Prep Plan (free!)Black Belt Case Prep Program: Your one-stop shop for case + fit interview prep, from round 1 to the offerYouTube playlist of Case Interview ExamplesStay on top of Consulting Application DeadlinesListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Welcome to the Daily Compliance News. Each day, Tom Fox, the Voice of Compliance, brings you compliance-related stories to start your day. Sit back, enjoy a cup of morning coffee, and listen in to the Daily Compliance News. All, from the Compliance Podcast Network. Each day, we consider four stories from the business world, compliance, ethics, risk management, leadership, or general interest for the compliance professional. Top stories include: BCG staff outraged by company's work to deport Gazans. (FT) What a bunch of branding clunkers. (FT) Should you rent a robot for compliance? (NYT) The challenges of responsible AI development. (Forbes) You can donate to flood relief for victims of the Kerr County flooding by going to the Hill Country Flood Relief here. Learn more about your ad choices. Visit megaphone.fm/adchoices

Willkommen zur neuen Folge von Choose Germany – dem Business-Punk-Podcast für alle, die dieses Land nicht schlechtreden, sondern neu gestalten wollen. In Partnerschaft mit dem Startup-Verband und powered by BCG holen wir Deutschlands mutigste Macher:innen ans Mikro.Zu Gast: Sebastian Pollok – Mitgründer des Deeptech-Fonds Visionaries Tomorrow, Serienunternehmer und Startup-Vordenker. Warum er überzeugt ist, dass Deeptech gerade seinen „Cloud-Moment“ erlebt, weshalb Familienunternehmen + Industrie der unterschätzte Hebel für Europas Technologieführung sind – und wie KI in der physischen Welt Produktionslinien, Energie und Logistik neu denkt.Sebastian spricht über drei Transformationen, in die sein Fonds investiert:Energie & Dekarbonisierung: von Fusionsenergie bis „Hydrogen Exploration“ – Technologien, die Versorgungssicherheit und CO₂-Bilanz gleichzeitig verbessern.Rohstoff-Resilienz & Zirkularität: neue Verfahren, die aus Abfallströmen Chemieprodukte machen und Abhängigkeiten von kritischen Ressourcen reduzieren.Physical AI & Robotics: KI, die auf der Werkbank wirkt – in Qualitätssicherung, Produktion, Logistik und Materialforschung.Dazu: Wie proprietäre Industriedaten zum Wettbewerbsvorteil werden (statt in fremde Modelle zu fließen), warum tiefere Kapitalmärkte & ein europäisches Exit-System entscheidend sind und weshalb Bürokratie-Fast-Tracks (à la FDA) Gründung und Skalierung spürbar beschleunigen.Es geht um:

Send us a textStep inside a live McKinsey-style case interview. In this episode, former McKinsey consultant and expert coach Mark Di Giorgio leads a candidate through a market entry case set in the nutrition and healthcare industry.Watch how the case unfolds, including:Structuring a US market entry problemSizing the diabetes supplement marketEvaluating retail vs. direct sales channelsAssessing risks and competitor responsesIf you're preparing for McKinsey, BCG, or Bain, this is your chance to experience the pressure of a real interview and learn how to communicate with structure, clarity, and confidence.Want personalized feedback and practice with Mark? Book a one-on-one coaching session today below. Spots fill quickly.Work with Mark:See Mark's current coaching availabilityPurchase the Black Belt case prep program for 1:1 coaching with Mark Connect on LinkedInPartner Links:Stax is hiring! See open roles and requirementsListen to the Market Outsiders podcast, the new daily show with the Management Consulted teamConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

In compliance, moments of uncertainty can define careers and reshape organizations. But what does it take to make sound judgments under intense pressure? How do you steer a team through a crisis without overpromising or losing trust?To explore these questions, our guest host and BCG senior executive Bernhard Gehra, is joined by senior compliance professional Satnam Lehal. In a wide-ranging discussion they touch on the difference between everyday problems and true crises, the risks of complacency, and why good leaders must be both detail-oriented and strategic. You'll hear candid insights on judgment, decision-making, and the importance of CEOs asking the right questions, even when nothing seems to be going wrong. About the show: BCG on Compliance is a podcast from Boston Consulting Group that explores today's most pressing criminal trends and how compliance experts are adapting to counter those threats.As financial crimes become increasingly sophisticated, compliance can no longer be just a checkbox. It's emerged as a transformative force in every industry, reshaping practices in ethics, risk management, money laundering and cyber security. On BCG on Compliance, we dive deep into the extraordinary minds that are driving that change.From crime prevention gurus to ethics champions, we'll ask provocative questions and bring you rich insights from the global players shaping the future of compliance, all in a dynamic and compact 20-minute episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Join us as we explore the profound ways compliance is altering industries around the globe. And connect with us at bcgoncompliance@bcg.comNew episodes are released monthly.

Is AI coming for your job? Boston Consulting Group's Global Lead for People and Organization, David Martin, reveals the truth about workforce disruption, survival strategies, reskilling, and the future of work.With only 20% of employees effectively using AI tools despite 80% expressing excitement, discover why adoption is failing and what leaders must do differently.

A Portfolio Prémium Banki Felméréséről beszélgettünk Árgyelán Ágnessel, Pénzügy rovatunk elemzőjével. 9700 milliárd forintos prémium banki vagyon és 670 ezer ügyfélszámla: a számok folyamatos növekedést mutatnak, ráadásul a „tagsághoz” havi szinten 400 ezer forintos fizetés is elég lehet. A műsor második részében arról volt szó, hogy – a COVID-éveket leszámítva – több mint egy évtized után először torpant meg a globális luxuspiac növekedése a Boston Consulting Group és az Altagamma kutatása szerint. A témában Lakatos-Török Györgyöt, a budapesti BCG partnerét, a fogyasztói trendek szakértőjét kérdeztük. Főbb részek: Intro – (00:00) Vagyonkezelés – (01:55) Luxusipar – (14:10) Kép forrása: Getty ImagesSee omnystudio.com/listener for privacy information.

從管顧業走進企業，是不少校友理想的職涯路線，但要怎麼活用所學、適應不同的職場環境，也是很多人在意的課題。 這一集，我們與 Chicago Booth 校友、Amer Sports 策略長 Victor 聊聊，在BCG 待了11年所獲得的經歷，如何幫助他轉型到運動產業，以及他形容的「闖關打怪」到底是什麼？一起來聆聽這集。 【內容重點】 1.管顧業與企業的工作文化差異 2.從 MBA 到管顧業，一路都在闖關打怪 3.職涯選擇時要思考的3個維度 【重點節錄】 02:30｜在 BCG 工作11年的心路歷程？ 07:00｜當初如何選擇在美國工作或回亞洲？ 25:00｜如何給 MBA 畢業兩三年、想要轉職卻有點猶豫的人一些建議？ 【瞭解更多MBA、職涯故事】⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠sabinahuang.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 【Facebook 粉絲頁】⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.facebook.com/sabinahuang.MBA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ -- Hosting provided by SoundOn

A CMO Confidential Interview with David Aaker, Vice Chair of Prophet, author of numerous marketing books including Aaker on Branding 2nd Edition, formerly a Haas School of Business Professor. David discusses the history of brand equity starting with the BCG model from the 90's and why that model and scanner data drove a short-term sales focus at the expense of brand equity. After years of progress, he believes we are now experiencing "A revival of short-termism." Key topics include: the differences between B2B and B2C brand building; the need for marketers to appreciate that brands aren't built in isolation; and how to break through in a hostile communications environment. Tune in to hear why he believes "There are easy ways for companies to build better brands," and case studies from Dove and Uniqlo. Brand value has been discussed for decades—so why isn't it a universally accepted business principle? In this episode of CMO Confidential, host Mike Linton sits down with branding legend David Aaker, Vice Chair at Prophet, author of 18 books, and widely regarded as the “Father of Modern Branding,” to unpack why the fight for brand equity is far from over.From the origins of brand equity in the 1990s to today's hostile marketing environment, Aaker shares insights on: • Why brand should be treated as a long-term asset, not a short-term tactic • How short-termism and performance marketing are eroding brand value • The difference between B2B and B2C brand management (and why organizational values matter more in B2B) • Examples of brands that have nailed disruptive innovation and purpose-driven branding (Dove, Uniqlo, Habitat for Humanity) • Why most companies are managing brands poorly in today's cluttered, skeptical media environment • How AI could democratize creativity and make professional branding accessible to more companiesPacked with history, frameworks, and practical examples, this conversation will change the way you think about brand value, brand portfolios, and how to make your brand truly indispensable.00:00 – Introduction to CMO Confidential & Guest David Aaker01:15 – Why Brand Value Still Isn't a Universally Accepted Principle03:45 – The Birth of Brand Equity in the 1990s06:10 – Short-Termism, Performance Marketing, and the Brand Erosion Problem08:35 – How to Justify Brand as an Asset (Case Studies & Examples)11:20 – The Visibility Advantage and 14 Dimensions of Brand Value13:05 – Why CFOs and Boards Believe in Other Brands, but Not Their Own15:10 – B2B vs B2C Branding: Key Differences and What Matters Most17:45 – Why Many Companies Are Managing Brands Poorly Today20:00 – Branding in a Hostile Communication Environment22:05 – The Power of Brand Portfolios, Companion Brands, and “Silver Bullet” Brands24:30 – Examples: Uniqlo, HeatTech, and the Westin Heavenly Bed26:10 – Super Bowl Advertising: Breaking Through Clutter and Skepticism28:00 – AI, the Democratization of Creativity, and the Future of Branding29:20 – Final Advice: Your Duty as a Marketer to Build the Brand as an Asset30:15 – Closing Remarks & SubscribeHere's your list fully hashtagged and comma-separated:#cmoconfidential, #DavidAaker, #brandvalue, #brandequity, #brandstrategy, #marketingstrategy, #brandingadvice, #B2Bbranding, #B2Cbranding, #brandmanagement, #shorttermism, #performancemarketing, #purposedrivenbranding, #DoveRealBeauty, #UniqloHeatTech, #HabitatforHumanity, #marketingleadership, #brandportfolio, #brandeddifferentiators, #brandedenergizers, #brandedsourceofcredibility, #hostilemediaenvironment, #disruptiveinnovation, #AIinbranding, #democratizationofcreativity, #CMOpodcast, #marketingpodcastSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

曾經高舉人道主義理想的以色列，如今在加薩走廊犯下的戰爭罪行，究竟是正義反擊，還是失控的種族清洗？ 《經濟學人》嚴厲指出，以色列將一開始正義的戰爭，演變成無止盡的死亡與破壞。加薩走廊大部分地區淪為廢墟，數百萬平民流離失所，而納坦雅胡政府甚至將糧食援助武器化，導致飢荒與死亡蔓延。更諷刺的是，哈馬斯早已被削弱，不足以對以色列構成威脅，這場戰爭已失去戰略意義。 哈瑪斯的罪行並不能為以色列開脫，作為一個民主國家。以色列應該用遠高於恐怖分子、軍閥和獨裁者的標準要求自己，關鍵在於以色列是否同意盡快停火、向加薩輸送充足物資，並在戰後成立真正獨立的調查委員會，否則這個誕生於1948年的理想國度，終將黯然失色。 主持人：天下雜誌資深主筆 黃亦筠 主講人：金庫資本管理合夥人兼總經理 丁學文 製作團隊：莊志偉、樂祈、邱宇豪 ＊延伸閱讀｜裁5千人、推1萬名「AI代理」，AI如何衝擊麥肯錫？：https://lihi.cc/142bT ＊立即收聽《天下學習Podcast》：https://hi.cw.com.tw/u/j7jy5LE/ ＊訂閱天下全閱讀：https://bit.ly/3STpEpV ＊意見信箱：bill@cw.com.tw -- Hosting provided by SoundOn

Episode 100: What started as a passion project has turned into a full career pivot!Four years ago, I hit record on the first episode of my podcast.I had no big plans. Just one question I couldn't stop thinking about:How do we live a good life?So I started How to Live.Shared what I'd learned.Stayed curious.Kept listening.Then something magical happened.I got a message from my old BCG boss, Dean Tong.We hadn't spoken in 15 years.He'd stumbled upon the podcast. We met.Talked about Stoicism, Buddhism, and Purpose.Then he invited me to speak at UOB Bank, where he was the Chief HR Officer.I was nervous. It was a corporate setting.I had a meditation exercise planned. Would it land?Dean said:“Don't worry. I'll take the risk. Just do your best.”That support changed everything.The talk worked.It led to more sessions. More companies.And one day I realised - this wasn't a side project anymore.It was a new path.Keynotes. Workshops. Leadership Programs.Helping leaders reconnect with purpose, reach their next peak, and navigate uncertainty with resilience.It felt meaningful.And it could pay the bills.So I took the leap.Sold my digital agency. Went all in.Today, I've led over 75 workshops across four continents with companies like Google, Unilever, HSBC, and Mastercard.And I've seen how powerful ancient wisdom can be in modern leadership.The podcast has grown beyond my wildest dreams too. Ranked in the top 3% globally and listened to in 150 countries.The lesson?When you do what you love with honesty and passion, it's infectious.People are watching. People are listening, even if they never like or comment.(Dean didn't either.)But sometimes, just one of them can change the trajectory of your entire life.

I had a blast sitting down with Dan Schaefer, Founder & CEO of Native Pet.  We kicked things off with gratitude. Dan shared how his wife was his “first angel investor,” backing his leap from BCG into entrepreneurship while raising a young family. From there, we got into the big idea behind Native Pet: “around-the-bowl nutrition.” Instead of trying to replace what's in your dog's bowl, Native Pet helps pet parents customize it with clean-label, effective supplements dogs actually love to eat. Dan walked me through their earliest wins, such as transforming messy canned pumpkin into a shelf-stable powdered pumpkin with a smart fiber blend, and their breakout hit, The Daily (an all-in-one scoop inspired by human greens routines). We also dug into hard-earned lessons (hello, Target packaging panic) and a huge upcoming launch that brings today's human gut-health wave into pet wellness. Highlights * Gratitude that fuels the journey: Dan credits his wife and co-founder Pat's family for believing early, packing boxes, cheering them on, and making “zero to one” possible.   * The Native Pet thesis: Focus on supplements to personalize health “around the bowl,” so pet parents can keep their preferred food and add targeted support.   * Simple, smart innovation: From powdered Pumpkin to Omega Oil, clean-label formats and taste are non-negotiable—if dogs won't eat it, nothing else matters.   * Breakout product: The Daily—their one-scoop daily multivitamin—became Native Pet's best seller and even hit #1 in multivitamins on Amazon right after Prime Day.   * Where to find them: Online at nativepet.com, Amazon, Chewy, and nationwide at Target, Petco, PetSmart, Whole Foods, Sprouts, Tractor Supply, Meijer, Pet Supplies Plus, and more.  Plus, try the website quiz to get the right plan for your dog.   * One more thing I'm excited about: Native Pet's new GutWell line (launching August) targets specific outcomes through the microbiome—Clean Breath, Trim Down, Stress Support, Itchy Skin, and Power Poop—in a tasty, clean-label, cold-pressed pellet with bold, premium packaging. Join me, Ramon Vela, in listening to the episode: If you care about helping your dog live a happier, healthier, and longer life—and want practical ways to personalize their nutrition—you'll love this conversation. Hit play to hear the full story, the lessons learned, and what's next for Native Pet.   For more on Native Pet, visit: https://nativepet.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review.  Plus, don't forget to follow us on Apple and Spotify.  Your support helps us bring you more content like this! * Today's Sponsors:   Saral - The Influencer OS: https://www.getsaral.com/demo SARAL is the all-in-one influencer platform that finds brand-aligned creators, automates outreach, and manages everything in one place. Request a live demo today. Let the SARAL team know you're a The Story of a Brand Show podcast listener to get an extended free trial! Visit the link above. 

How do you effectively treat your bladder cancer population with an insufficient supply of BCG? Dr. Amy Luckenbaugh, a urologic oncologist at Vanderbilt University Medical Center, joins host Dr. Ruchika Talwar to highlight challenges and solutions to managing bladder cancer amidst ongoing BCG shortages. --- This podcast is supported by an educational grant from UroGen Pharma. --- SYNPOSIS Dr. Luckenbaugh and Dr. Talwar delve into the history and significance of BCG in bladder cancer treatment, exploring the reasons behind the shortages and discussing various coping strategies, including split dosing and alternative intravesical therapies like gemcitabine, docetaxel, and the new mitomycin hydrogel. The conversation also covers emerging treatments for high-risk patients, the role of radical cystectomy, and the importance of standardization and innovation in dealing with medication shortages. Dr. Luckenbaugh highlights the importance of patient quality of life, cost considerations, and the need for resilient pharmaceutical supply chains. --- TIMESTAMPS 00:00 - Introduction01:56 - History and Importance of BCG in Bladder Cancer03:21 - Challenges and Shortages of BCG06:36 - Managing BCG Shortages in Clinical Practice12:33 - New Alternatives and Treatments for Bladder Cancer23:28 - The Role of Cystectomy in Bladder Cancer Treatment26:12 - Future Directions and Final Thoughts --- RESOURCES BCG Shortage AUA Recommendations:https://www.auanet.org/about-us/bcg-shortage-info Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre: https://pmc.ncbi.nlm.nih.gov/articles/PMC11951178/ Bladder Cancer Advocacy Network (BCAN):https://bcan.org/ Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)https://pubmed.ncbi.nlm.nih.gov/39446087/b FDA Approves Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle TAR-200 - SunRISe-3 Study:https://www.jnjmedicalconnect.com/products/tar-200/medical-content/tar-200-sunrise-3-study First results from TAR-200 - SunRISe-1 Study:https://www.jnj.com/media-center/press-releases/johnson-johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibcN-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review:https://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/

At the end of 2023, the Society of Automobile Engineers (SAE) sponsored a report from consulting firm BCG called “The US Needs More Engineers. What's the Solution?” in December 2023. It showed that the United States is facing a massive shortage of engineers. In this episode of Control Intelligence, written by contributing editor Joey Stubbs, editor in chief Mike Bacidore discusses IEC 61131-3 language portability.

With a background spanning operational leadership at Rolls-Royce, strategic advisory at BCG, and now sustainable investing at IMCO, Youssef Aroub brings sharp analysis to the intersection of nature and private markets. In this episode, Jenn and Youssef explore why biodiversity is climbing the investor agenda and how businesses can start weaving nature considerations into their core strategy. From data centres in drought zones to cocoa supply chains driving deforestation, nature risk is increasingly business risk. Youssef explains how to start turning that risk into opportunity.Useful Links:Follow Youssef on LinkedIn hereLearn more about IMCO's work hereRead Youssef's book recommendation, Candide, hereClick here for the episode web page. This episode is also available on YouTube.For more insights straight to your inbox subscribe to the Future in Sight newsletter, and follow us on LinkedIn and Instagram This podcast is brought to you by Re:Co, a tech-powered advisory company helping private market investors pursue sustainability objectives and value creation in tandem. Produced by Chris AttawayArtwork by Harriet RichardsonMusic by Cody Martin

Private equity is under pressure to deliver returns in a tougher environment. Clark O'Niell, BCG's global lead for AI infrastructure and cyber in the private investors & private equity practice, shares how the smartest investors are using AI to move beyond hype, drive impact at scale, and future-proof their portfolios. It's about focus over fragmentation—and combining judgment with new tools. Learn More: Clark O'Niell: https://on.bcg.com/46tTmep BCG's Latest Thinking on Private Equity: https://on.bcg.com/4598Fa5 IT Spending Pulse: AI Agents and GenAI Reshape Priorities: https://on.bcg.com/4mmjVXG The So What from BCG on YouTube: https://www.youtube.com/playlist?list=PLMJgyXjV5gMI9JV-GcF_D1Y6zyf1Eab_0This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us a textWatch as a former BCG consultant - Raghav - leads a candidate through a real-time case interview focused on cost reduction for a defense contractor. This live case tests structuring, market sizing, math under pressure, and strategy formulation.You'll learn how to:Break down a cost-focused BCG-style caseHandle unfamiliar industry contexts like defense manufacturingStructure a winning recommendation with limited dataAvoid common case math pitfallsStick around for detailed feedback from Raghav to sharpen your own case skills.Want personalized prep like this? Join Black Belt today.Work with Raghav:See Raghav's coaching calendarPurchase the Black Belt case prep program for 1:1 coaching with Raghav Connect on LinkedInPartner Links:Stax is hiring! See open roles and requirementsConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Insider trading doesn't always start with a grand plan. Sometimes it starts with a single decision made in isolation.In this episode, we talk to Tom Hardin, a former hedge fund analyst turned FBI informant, known in headlines as “Tipper X.” Tom opens up about his descent into insider trading, what it was like to wear a wire for the FBI and the personal and professional aftermath of becoming one of the most prolific cooperating witnesses in modern financial crime history.We explore how decisions made in isolation can quietly undermine compliance, and how culture, oversight, and mentorship can be the most powerful internal controls an organization has.About the Show:BCG on Compliance is a podcast from Boston Consulting Group that explores today's most pressing criminal trends and how compliance experts are adapting to counter those threats.As financial crimes become increasingly sophisticated, compliance can no longer be just a checkbox. It's emerged as a transformative force in every industry, reshaping practices in ethics, risk management, money laundering and cyber security. On BCG on Compliance, we dive deep into the extraordinary minds that are driving that change.Hosted by Hanjo Seibert, a leading expert in compliance, anti-financial crime and fraud, BCG on Compliance features interviews with heavy-hitters propelling compliance to the forefront of the industry. From crime prevention gurus to ethics champions, we'll ask provocative questions and bring you rich insights from the global players shaping the future of compliance, all in a dynamic and compact 20-minute episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Join us as we explore the profound ways compliance is altering industries around the globe. And connect with us at bcgoncompliance@bcg.comNew episodes are released monthly. Listen wherever you get your podcasts.Hanjo Seibert LinkedInBCG LinkedInBCG websiteTipper X

Robyn Bolton is the Founder and Chief Navigator at MileZero, a consultancy that helps leaders of $100M companies use innovation to confidently and repeatedly grow revenue. She previously worked at Innosight, BCG, and Procter & Gamble, where she helped develop and launch the Swiffer product. Robyn holds an MBA from Harvard Business School and a BS in Marketing from Miami University. Her articles and perspectives have been featured in Fast Company, Harvard Business Review Online, The New York Times, and NPR's Marketplace.Contact Robyn Bolton: Book:  unlockinginnovation.co or https://amzn.to/4kC5qygwww.milezero.ioLinkedIn:  https://www.linkedin.com/in/robynmbolton/https://www.milezero.io/about/Radical Empowerment Method Book on Amazon: https://amzn.to/3Bdp2BCBook CarrieVee for a Speaking Engagement:  https://www.coachcarriev.com/contact-meJoin the Confidence and Clarity Membership!  https://carrievee.com/confidence-clarity-1Schedule your Discovery Call with CarrieVee!https://schedulewithcarrievee.as.me/?appointmentType=12343596

durée : 00:39:08 - France Culture va plus loin (l'Invité(e) des Matins d'été) - par : Julie Gacon, Sarah Masson - Le Financial Time a révélé que le cabinet de conseil américain BCG s'est penché sur le projet de la Gaza Riviera, souhaité par Donald Trump. Pendant sept mois, une douzaine d'employés ont travaillé sur cette initiative, établi sans les gazaouis et facturé plusieurs millions de dollars. - réalisation : Sam Baquiast, Vivian Lecuivre - invités : David Naïm Consultant en stratégie, “Associé” dans l'un des plus gros cabinets de conseil du monde

Sheinbaum felicita a clavadistas mexicanas por ganar medalla de bronceGolpe a los cárteles de la droga, decomisan 20 millones de pesos Las primeras gafas de la historia se usaron para la vista cansada  Más información en nuestro podcast

Send us a textKatie Neff's path to consulting was anything but typical. After 8 years in the Marine Corps, she pivoted through a dual degree at Columbia and went on to land a role with BCG in the Middle East.In this conversation, Katie unpacks how she:Built a strong consulting resumeNavigated hidden BCG networking opportunitiesMastered case interview prep with the Black Belt programNailed the offer from a nontraditional backgroundHer story is packed with BCG recruiting tips, consulting career advice, and encouragement for anyone looking to break into a top consulting firm.Additional Resources:Black Belt: Get the same edge Katie used to land her BCG offer with coaching, resume edits, networking strategies, and case prepResume Template: Use our 1‑page consulting resume template to stand outCase  Prep Plan: Follow our step‑by‑step plan to master cases with the right structure, practice schedule, and toolsPartner Links:Stax is hiring! See open roles and requirementsConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

The global strategy consulting market stands at $39.5 billion, with Asia commanding $9.1 billion. India contributes just $1.09 billion. This is despite having the talent; Indians run global back-offices for McKinsey, BCG, Bain, Deloitte, and other consultancies. Yet, India continues to outsource strategy to the Big 4.Sanjeev Sanyal, PM Modi's Economic Advisor joins us to break this down.We discuss the factors helping and hindering India's growth opportunities. Sanjeev has long worked on improving the process reforms with the belief that this country needs small reforms that will bring huge impact.We also discuss AI, with a policymaker who strongly believes unregulated AI will be catastrophic. Sanjeev shares his opinions on what could be the government's approach to regulation, with acceptance of the limited predictability of future with AI.If you want to understand India from a policymaker's eye this episode is for you.0:00- Trailer0:55 – Why India Needs Many Small Reforms2:50 – Was WFH Technically Illegal Until 2000?3:57 – India as the GCC Capital for the world7:02 – How did India go from filing 6,000 to 1 Lakh Patents?13:45 – Why India Can't build Its Own Big 4+317:40 – When professional bodies in India don't work together21:05 – What happens when branding is banned?24:08 – Restrictions That need to stay27:11 – How India's IT Sector Grew Without a Governing Body30:06 – Are we risking catastrophic failure with Unregulated AI?36:10 – Can We Regulate AI Like the Stock Market?41:39 – Why India Must Shut down Population Control47:10 – Will AI Replace Lawyers and Accountants?49:14 – What India Isn't Ready For?51:31 – India as a historically risk taking nation54:31 – Why are professional bodies holding onto protection?56:55 – The Business Culture Problem in Kolkata58:32 – Sanjeev's Work in Agroforestry-------------India's talent has built the world's tech—now it's time to lead it.This mission goes beyond startups. It's about shifting the center of gravity in global tech to include the brilliance rising from India.What is Neon Fund?We invest in seed and early-stage founders from India and the diaspora building world-class Enterprise AI companies. We bring capital, conviction, and a community that's done it before.Subscribe for real founder stories, investor perspectives, economist breakdowns, and a behind-the-scenes look at how we're doing it all at Neon.-------------Check us out on:Website: https://neon.fund/Instagram: https://www.instagram.com/theneonshoww/LinkedIn: https://www.linkedin.com/company/beneon/Twitter: https://x.com/TheNeonShowwConnect with Siddhartha on:LinkedIn: https://www.linkedin.com/in/siddharthaahluwalia/Twitter: https://x.com/siddharthaa7-------------This video is for informational purposes only. The views expressed are those of the individuals quoted and do not constitute professional advice.Send us a text

“Businesses are wasting more money than they're making.” This stark assessment from serial entrepreneur Paul Polizzotto frames a provocative question: what if procurement's greatest untapped opportunity lies not in negotiating better prices, but in redirecting the millions corporations already squander on ineffective sales and marketing spend? In this episode of "Buy: The Way...To Purposeful Procurement," Paul Polizzotto, founder of Community AI and former CEO of EcoMedia (which was sold to CBS), joins co-hosts Philip Ideson and Rich Ham to explore how procurement can transform transactional moments into powerful engines for social impact - without paying a penny more for goods and services. Paul's track record speaks for itself: at EcoMedia, he redirected over $600 million of incremental advertising revenues toward community projects, powering solar installations on schools and city halls (including making Miami's City Hall the first major municipal building powered entirely by renewable energy), while making CBS more profitable. The secret? Tapping into the 10-30 percent of gross revenues that Fortune 500 companies routinely waste on ineffective SG&A expenses. The conversation reveals a fundamental misunderstanding about social impact procurement.  While procurement teams worry about paying extra for "do-good" initiatives, Paul demonstrates how suppliers can fund meaningful community projects from their existing – and often wasteful – advertising, marketing, and event budgets. These are dollars that currently provide zero value, yet can be redirected to create measurable local impact while strengthening supplier relationships. As Paul notes, 92 percent of CEOs surveyed by BCG believe that embedding social impact in procurement significantly elevates the function's importance and relevance within their organizations. If procurement seeks to demonstrate value beyond traditional cost savings, community impact offers a measurable, strategic pathway to C-suite relevance.   Links: Paul Polizzotto on LinkedInRich Ham on LinkedInLearn more at FineTuneUs.com  

Shoot us a Text.Episode #1102: Today, we're unpacking the Detroit 3's tariff turmoil with Japan, exploring how "Auction 2.0" is reshaping used-car sourcing, and tracking Delta's AI-driven pricing turbulence as Senators demand answers. The U.S. automakers GM, Ford, and Stellantis are pushing back against a new trade deal lowering Japanese auto tariffs to 15%, while tariffs on Canadian and Mexican imports stay at 25%. The Detroit 3 warn this imbalance threatens U.S. auto jobs and industry.Matt Blunt of the American Automotive Policy Council says any deal that favors Japanese imports over high-U.S.-content North American vehicles is “a bad deal for U.S. industry and auto workers.”President Trump boasts of a “massive deal” with Japan involving $550 billion in investments and tariff cuts, calling it a historic win for U.S. automakers.Details remain murky on whether Japanese cars and parts will get carve-outs from existing tariffs; the deal comes as Trump threatens to hike tariffs on Mexico and Canada.U.S.-Japan talks included Japan's chief trade negotiator meeting Treasury Secretary Scott Bessent, who says negotiations are “going very well.”Japanese automakers continue investing in U.S. production, with significant commitments from Isuzu and Toyota, aiming to boost local manufacturing despite tariff concerns.According to recent data from Cox Automotive, NADA, and BCG, the traditional used-car auction model is failing franchised dealers due to rising fees, transport costs, and poor condition reports. Dealers are shifting fast to private-party acquisitions (PPA), creating a more local and cost-effective supply.Auction-sourced dealer inventory fell from 27% in 2019 to 18% in 2023, while private-party sourcing grew from 10% to 15%.Buy fees have increased by about 50%, transport costs are up roughly a third, and lane prices remain inflated, squeezing dealer margins.The Manheim Index peaked at 234 in early 2023, but lane conversion rates dropped to 58-64%, below the 70% pre-pandemic norm.NADA projects private-party sales will hit 40% of the used market by 2025, signaling a permanent market shift.According to Sen. Ruben Gallego and other senators, Delta's new AI-based ticket pricing strategy could unfairly hike costs based on individual passenger data. Senators worry this could squeeze consumers financially during tough economic times.Senators are demanding clarity on what data Delta uses and how widely the AI pricing will be implemented, currently 3% but planned for 20% of routes by year-end.Delta says the AI tech streamlines longstanding dynamic pricing and denies using personal data for individualized offers.Critics worry AI could push prices to each consumer's “pain point,” risking predatory pricing amid inflation pressures.Delta preJoin Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Rich Lesser, BCG's global chair, and Martin Reeves, chairman of the BCG Henderson Institute, reflect on the shocks and surprises that shaped the first half of the decade and what they reveal about the future. They explore the traits leaders need today: building trust, staying geopolitically aware, and adopting AI in a people-centered way. Learn More: Rich Lesser: https://on.bcg.com/4lZrWla Martin Reeves: https://on.bcg.com/4lXaAVX Winning in the 20s: https://on.bcg.com/4lpe1oo Winning the '20s: A Leadership Agenda for the Next Decade: https://on.bcg.com/40iscDs This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Top consulting firms have repeatedly found themselves facing a reputational crisis. The most recent example was in early July, when a Financial Times investigation revealed that Boston Consulting Group had modelled a plan to ‘relocate' Palestinians from Gaza after entering into a multimillion-dollar contract to help launch an aid scheme for the enclave. In this week's episode, the FT's US accounting editor, Stephen Foley, explains his reporting and examines what these events say about how effective the consulting industry's ability to avoid reputational scandals is. Clips from the UN - - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:BCG modelled plan to ‘relocate' Palestinians from GazaInside Gaza's ‘death traps'The little-known group poised to take over Gaza's aidBCG gets caught up in a scandal in Gaza - - - - - - - - - - - - - - - - - - - - - - - - - - Follow Stephen Foley on X (@stephenfoley) and Bluesky (‪@stephenfoleyft.bsky.social‬). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Life-saving drugs exist for many diseases, yet millions still lack access due to manufacturing inefficiencies and high costs. Our next guest, Reza Farahani, is revolutionizing this challenge as founder and CEO of Katalyze AI. As a third-time founder with two successful exits and strategic consulting experience at BCG, Reza brings a unique perspective to biomanufacturing optimization. His company is pioneering agentic AI solutions that act as specialized co-pilots, combining the expertise of data engineers, scientists, and process engineers into powerful automation tools. Driven by a mission to make essential medicines accessible and affordable for everyone, Reza shares how Katalyze AI is helping pharmaceutical companies increase efficiency, reduce costs, and minimize waste. Join us to discover how AI-powered biomanufacturing is transforming drug production and creating a future where life-saving treatments are within reach for all communities. Let's go!Episode Highlights:Bias Towards Action: Reza's #1 advice for entrepreneurs is taking action over endless planning - he even encourages new team members to make mistakes in their first few monthsMillion Dose Impact: Katalyze AI helped a pharmaceutical company ship one million extra vaccine doses without any capital investment, just by optimizing standard operating proceduresData Goldmine Unlocked: The company created specialized digitization tools to extract valuable insights from unstructured PDFs and lab notes that were previously inaccessibleFuture of Bio-Manufacturing: Reza envisions making everyday products like milk through bio-manufacturing at 10X lower costs with 90% less energy and 60% less waterAgentic AI Solutions: Katalyze AI acts as a specialized co-pilot combining data engineering, science, and process engineering expertise to help one person solve complex manufacturing problemsRetryClaude can make mistakes. Please double-check responses.About our Guest: Reza is a third-time founder with two successful exits, reflecting his strong track record in launching and scaling technology ventures. Before founding Katalyze AI, he gained strategic consulting experience at BCG, where he focused on driving data-driven solutions for diverse industries. He holds a Master's degree in System Design Engineering from the University of Waterloo. His leadership establishes the company as a trusted partner in biomanufacturing.Links Supporting This Episode: Katalyze AI Website: CLICK HEREReza Farahani LinkedIn page: CLICK HEREKatalyze AI LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK...

Europe is at a tipping point after years of slow growth. Sylvain Duranton, BCG X's global leader, explains how countries and companies can work together to simplify regulation, scale innovation, and build a truly unified, competitive Europe. Learn More: Sylvain Duranton:https://on.bcg.com/3T9QN9b Europe's Business Leaders Are Ready for Action: https://www.linkedin.com/pulse/global-trade-disruption-wake-up-call-europe-boston-consulting-group-lbnhe/ BCG's Center for Geopolitics: https://on.bcg.com/4kJir8K This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp